Changes to the Code
H.R. 3631 · Vaccines in Trial and Liability Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
VITAL Act of 2025
In committee · step 2 of 5
18 U.S.C. § 1041 Clinical vaccine trial fraud New section
1 change the bill asks for here, 1 carried out
- Carried out:
Chapter 47 of title 18, United States Code, is amended by adding at the end the following:1041. Clinical vaccine trial fraud Whoever, being a medical research company or sponsor, makes a fraudulent statement to, or conceals from, any department or agency of the United States, any material data collected from a clinical vaccine trial, shall be fined under this title, imprisoned not more than 5 years, or both..
§ 1041
§ 1041. [inserted: Clinical vaccine trial fraud]
[inserted: Whoever, being a medical research company or sponsor, makes a fraudulent statement to, or conceals from, any department or agency of the United States, any material data collected from a clinical vaccine trial, shall be fined under this title, imprisoned not more than 5 years, or both.]
21 U.S.C. § 360bbb–3 Authorization for medical products for use in emergencies
6 changes the bill asks for here, 6 carried out
- Carried out:
in paragraph (4), by striking
and
; - Carried out:
by redesignating paragraph (5) as paragraph (6); and
- Carried out:
by inserting after paragraph (4) the following:
(5) the authorization is based on a certification by a medical research company or sponsor that no fraudulent material statements were made, and no material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under this subsection; and.
- Carried out:
in subparagraph (B), by striking
or
at the end; - Carried out:
by redesignating subparagraph (C) as subparagraph (D); and
- Carried out:
by inserting after subparagraph (B) the following:
(C) the Secretary determines that fraudulent material statements were made, or material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under subsection (c); or.
§ 360bbb–3(c)–(d)
Start of § 360bbb–3 to (c)(2)(B) unchanged ·
(3) that there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating such disease or condition;
(4) in the case of a determination described in subsection (b)(1)(B)(ii), that the request for emergency use is made by the Secretary of Defense;[struck: and]
(5) [inserted: the authorization is based on a certification by a medical research company or sponsor that no fraudulent material statements were made, and no material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under this subsection; and]
[struck: (5)] [inserted: (6)] that such other criteria as the Secretary may by regulation prescribe are satisfied.
(d) Scope of authorization An authorization of a product under this section shall state—
(1) each disease or condition that the product may be used to diagnose, prevent, or treat within the scope of the authorization;
§ 360bbb–3(g)–(h)
(d)(2)–(g)(2) unchanged ·
(A) the circumstances described under subsection (b)(1) no longer exist;
(B) the criteria under subsection (c) for issuance of such authorization are no longer met;[struck: or]
(C) [inserted: the Secretary determines that fraudulent material statements were made, or material information was concealed, with respect to the circumstances described under subsection (b)(1) or the criteria under subsection (c); or]
[struck: (C)] [inserted: (D)] other circumstances make such revision or revocation appropriate to protect the public health or safety.
(h) Publication; confidential information
(1) Publication The Secretary shall promptly publish on the internet website of the Food and Drug Administration and in the Federal Register a notice of each authorization, and each termination or revocation of an authorization under this section, and an explanation of the reasons therefor (which may include a summary of data or information that has been submitted to the Secretary in an application, request, or submission under this section or section 355(b), 355(i), 355(j), 360b(b), 360b(j), 360b(n), 360e, 360(k), 360c(f)(2), 360j(g), 360j(m), 360ccc, or 360ccc–1 of this title, or section 351(a) or 351(k) of the Public Health Service Act [42 U.S.C. 262(a), (k)], even if such summary may reveal the existence of such an application, request, or submission, or data contained in such application, request, or submission). The Secretary shall make any revisions to an authorization under this section available on the Internet Web site of the Food and Drug Administration, which may include a summary of the data and information supporting such revisions.
Rest of § 360bbb–3 unchanged ·
42 U.S.C. § 247d–6d Targeted liability protections for pandemic and epidemic products and security countermeasures
13 changes the bill asks for here, 11 carried out
- Carried out:
by redesignating clauses (i), (ii), and (iii) as subclauses (I), (II), and (III), respectively;
- Carried out:
by striking the period at the end of subclause (III) and inserting
; and
, as redesignated; - Not carried out:
by striking the period at the end of subclause (III) and inserting ; and, as redesignated;
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: as redesignated; - Not carried out:
by striking subsection (d), denote and inserting the following:(i) denote subsection (d)—; and
§ 247d–6d(c)(1)(A) already has provisions of its own, so its opening words can't simply become the first of them.
Technical detail
/us/usc/t42/s247d–6d/c/1/A has provisions already, so its words can't become the first - Carried out:
by adding at the end the following:
(ii) includes— (I) making a fraudulent material statement with respect to data collected from a clinical trial; or (II) concealing material information with respect to data collected from a clinical trial.; and
- Carried out:
in the matter preceding clause (i), by striking
subsection (d) if—
and insertingsubsection (d)—
; - Carried out:
by inserting
if
beforeneither
; and - Carried out:
by striking
or
at the end; - Carried out:
by inserting
if
beforesuch an enforcement
; and - Carried out:
by striking the period at the end and inserting
; and
; and - Carried out:
by adding at the end the following:
(iii) unless the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or material information was concealed, by a covered person with respect to data collected from a clinical trial of a covered countermeasure.; and
- Carried out:
by striking paragraph (7); and
- Carried out:
by adding at the end the following:
(11) Award of damages.— Notwithstanding any other provision of law, the amount of an award of damages made to a plaintiff may not be reduced because of any other award for damages the plaintiff may receive as a result of such claim..
§ 247d–6d(c)Definition of willful misconduct(1)–(2)
Start of § 247d–6d to (c) unchanged ·
(1) Definition
(A) In general Except as the meaning of such term is further restricted pursuant to paragraph (2), the term “willful misconduct” shall, for purposes of subsection (d), denote an act or omission that is taken—
[struck: (i)] [inserted: (I)] intentionally to achieve a wrongful purpose;
[struck: (ii)] [inserted: (II)] knowingly without legal or factual justification; and
[struck: (iii)] [inserted: (III)] in disregard of a known or obvious risk that is so great as to make it highly probable that the harm will outweigh the benefit[struck: .][inserted: ; and]
(ii) [inserted: includes—]
(I) [inserted: making a fraudulent material statement with respect to data collected from a clinical trial; or]
(II) [inserted: concealing material information with respect to data collected from a clinical trial.]
(B) Rule of construction The criterion stated in subparagraph (A) shall be construed as establishing a standard for liability that is more stringent than a standard of negligence in any form or recklessness.
(2) Authority to promulgate regulatory definition
§ 247d–6d(c)Definition of willful misconduct(4)–(5)
(c)(2)(A)–(3) unchanged ·
(4) Defense for acts or omissions taken pursuant to Secretary’s declaration Notwithstanding any other provision of law, a program planner or qualified person shall not have engaged in “willful misconduct” as a matter of law where such program planner or qualified person acted consistent with applicable directions, guidelines, or recommendations by the Secretary regarding the administration or use of a covered countermeasure that is specified in the declaration under subsection (b), provided either the Secretary, or a State or local health authority, was provided with notice of information regarding serious physical injury or death from the administration or use of a covered countermeasure that is material to the plaintiff’s alleged loss within 7 days of the actual discovery of such information by such program planner or qualified person.
(5) Exclusion for regulated activity of manufacturer or distributor
(A) In general If an act or omission by a manufacturer or distributor with respect to a covered countermeasure, which act or omission is alleged under subsection (e)(3)(A) to constitute willful misconduct, is subject to regulation by this chapter or by the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.], such act or omission shall not constitute “willful misconduct” for purposes of subsection (d)[struck: if]—
(i) [struck: neither][inserted: ifneither] the Secretary nor the Attorney General has initiated an enforcement action with respect to such act or omission;[struck: or]
(ii) [struck: such][inserted: ifsuch] an enforcement action has been initiated and the action has been terminated or finally resolved without a covered remedy[struck: .][inserted: ; and]
(iii) [inserted: unless the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or material information was concealed, by a covered person with respect to data collected from a clinical trial of a covered countermeasure.]
Any action or proceeding under subsection (d) shall be stayed during the pendency of such an enforcement action.
(B) Definitions For purposes of this paragraph, the following terms have the following meanings:
§ 247d–6d(e)–(g)
(c)(5)(B)(i)–(e)(6)(A)(ii) unchanged ·
(iii) in the event a covered person files an interlocutory appeal from the denial of such a motion, before the court of appeals has ruled on such appeal.
(B) Standard Notwithstanding any other provision of law, the court in an action under subsection (d) shall permit discovery only with respect to matters directly related to material issues contested in such action, and the court shall compel a response to a discovery request (including a request for admission, an interrogatory, a request for production of documents, or any other form of discovery request) under Rule 37, Federal Rules of Civil Procedure, only if the court finds that the requesting party needs the information sought to prove or defend as to a material issue contested in such action and that the likely benefits of a response to such request equal or exceed the burden or cost for the responding party of providing such response.
[struck: (7)] [struck: Reduction in award of damages for collateral source benefits]
[struck: (A)] [struck: In general] [struck: In an action under subsection (d), the amount of an award of damages that would otherwise be made to a plaintiff shall be reduced by the amount of collateral source benefits to such plaintiff.]
[struck: (B)] [struck: Provider of collateral source benefits not to have lien or subrogation] [struck: No provider of collateral source benefits shall recover any amount against the plaintiff or receive any lien or credit against the plaintiff’s recovery or be equitably or legally subrogated to the right of the plaintiff in an action under subsection (d).]
[struck: (C)] [struck: Collateral source benefit defined] [struck: For purposes of this paragraph, the term “collateral source benefit” means any amount paid or to be paid in the future to or on behalf of the plaintiff, or any service, product, or other benefit provided or to be provided in the future to or on behalf of the plaintiff, as a result of the injury or wrongful death, pursuant to—]
[struck: (i)] [struck: any State or Federal health, sickness, income-disability, accident, or workers’ compensation law;]
[struck: (ii)] [struck: any health, sickness, income-disability, or accident insurance that provides health benefits or income-disability coverage;]
[struck: (iii)] [struck: any contract or agreement of any group, organization, partnership, or corporation to provide, pay for, or reimburse the cost of medical, hospital, dental, or income disability benefits; or]
[struck: (iv)] [struck: any other publicly or privately funded program.]
(8) Noneconomic damages In an action under subsection (d), any noneconomic damages may be awarded only in an amount directly proportional to the percentage of responsibility of a defendant for the harm to the plaintiff. For purposes of this paragraph, the term “noneconomic damages” means damages for losses for physical and emotional pain, suffering, inconvenience, physical impairment, mental anguish, disfigurement, loss of enjoyment of life, loss of society and companionship, loss of consortium, hedonic damages, injury to reputation, and any other nonpecuniary losses.
(9) Rule 11 sanctions Whenever a district court of the United States determines that there has been a violation of Rule 11 of the Federal Rules of Civil Procedure in an action under subsection (d), the court shall impose upon the attorney, law firm, or parties that have violated Rule 11 or are responsible for the violation, an appropriate sanction, which may include an order to pay the other party or parties for the reasonable expenses incurred as a direct result of the filing of the pleading, motion, or other paper that is the subject of the violation, including a reasonable attorney’s fee. Such sanction shall be sufficient to deter repetition of such conduct or comparable conduct by others similarly situated, and to compensate the party or parties injured by such conduct.
(10) Interlocutory appeal The United States Court of Appeals for the District of Columbia Circuit shall have jurisdiction of an interlocutory appeal by a covered person taken within 30 days of an order denying a motion to dismiss or a motion for summary judgment based on an assertion of the immunity from suit conferred by subsection (a) or based on an assertion of the exclusion under subsection (c)(5).
(11) [inserted: Award of damages.—] [inserted: Notwithstanding any other provision of law, the amount of an award of damages made to a plaintiff may not be reduced because of any other award for damages the plaintiff may receive as a result of such claim.]
(f) Actions by and against the United States Nothing in this section shall be construed to abrogate or limit any right, remedy, or authority that the United States or any agency thereof may possess under any other provision of law or to waive sovereign immunity or to abrogate or limit any defense or protection available to the United States or its agencies, instrumentalities, officers, or employees under any other law, including any provision of chapter 171 of title 28 (relating to tort claims procedure).
(g) Severability If any provision of this section, or the application of such provision to any person or circumstance, is held to be unconstitutional, the remainder of this section and the application of such remainder to any person or circumstance shall not be affected thereby.
Rest of § 247d–6d unchanged ·
42 U.S.C. § 300aa–22 Standards of responsibility
1 change the bill asks for here, 1 carried out
- Carried out:
Section 2122 of the Public Health Service Act (42 U.S.C. 300aa–22) is amended by adding at the end the following:
(f) Liability.— (1) Fraudulent material statement.— No civil action against a vaccine manufacturer or vaccine sponsor shall be barred under this part if the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or …
§ 300aa–22(d)–(f)
Start of § 300aa–22 to (c) unchanged ·
(d) Construction The standards of responsibility prescribed by this section are not to be construed as authorizing a person who brought a civil action for damages against a vaccine manufacturer for a vaccine-related injury or death in which damages were denied or which was dismissed with prejudice to bring a new civil action against such manufacturer for such injury or death.
(e) Preemption No State may establish or enforce a law which prohibits an individual from bringing a civil action against a vaccine manufacturer for damages for a vaccine-related injury or death if such civil action is not barred by this part.
(f) [inserted: Liability.—]
(1) [inserted: Fraudulent material statement.—] [inserted: No civil action against a vaccine manufacturer or vaccine sponsor shall be barred under this part if the Secretary determines, after notice and opportunity for a hearing, that a fraudulent material statement was made, or material information was concealed, by a vaccine manufacturer with respect to data collected from a clinical trial of a vaccine.]
(2) [inserted: Award of damages.—]
(A) [inserted: In general.—] [inserted: Notwithstanding any other provision of law, an plaintiff bringing a claim pursuant to paragraph (1) may—]
(i) [inserted: seek compensation under the program established under this part; and]
(ii) [inserted: concurrently bring an action with respect to such claim in any appropriate United States district court.]
(B) [inserted: Award of damages.—] [inserted: Notwithstanding any other provision of law, the amount of an award of damages made to a plaintiff for a claim pursuant to paragraph (1) may not be reduced on the basis of any other damages the plaintiff may receive as a result of such claim.]
(3) [inserted: Applicability with respect to COVID–19 vaccine.—] [inserted: Notwithstanding any other provision of law, a civil action against a vaccine manufacturer pursuant to paragraph (1) with respect to a vaccine related to COVID–19 may be made at any time.]
(4) [inserted: COVID–19 definition.—] [inserted: In this section, the term “COVID–19” means the coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 or the SARS–CoV–2. This term also relates to any and all variations of that virus of which there is no termination date for this term.]